Ro Health stock
Private-market facts for current and former Ro Health employees researching their stock.
Overview
Ro is a direct-to-patient telehealth company offering online diagnosis, treatment, and pharmacy delivery for conditions including weight loss, men's health, and fertility.
Ro Health outlook
For employees evaluating Ro Health equity, a 1x base multiple suggests the stock may be close to fairly valued at current prices.
These estimates reflect modeled return scenarios, not guaranteed outcomes. Actual results depend on company performance, market conditions, share class, and timing.
Selling Ro Health shares
Why shareholders consider selling
Shareholders in Ro Health may explore liquidity for a number of reasons — diversifying a concentrated position, funding a personal financial goal, or simply reducing exposure to a single private holding. As a private company, Ro Health does not trade on a public exchange, meaning employees and early shareholders cannot simply sell through a brokerage. Extended private timelines can leave shareholders waiting years for an exit event, which is why some choose to explore secondary-market options.
Can you sell Ro Health stock?
Whether a shareholder can sell typically depends on what they hold and how it was acquired. Vested and exercised shares are generally more straightforward than unexercised options or unvested RSUs. Most private companies, including those in the Healthcare & Biotech sector, impose transfer restrictions such as rights of first refusal or board approval requirements. The specific terms governing Ro Health shares would be outlined in the holder's equity agreement or the company's governing documents.
What affects the value of Ro Health shares?
The price a buyer is willing to pay for private shares is shaped by several factors: overall demand for the stock, the company's financial performance, broader Healthcare & Biotech market conditions, and any recent private-market transaction activity. Data points such as the company's Series D round and its reported $7B valuation can help frame expectations, though they do not guarantee a transaction price.
What should holders check before selling
- The type of security held (common shares, preferred, options, RSUs)
- Whether the equity is fully vested and, for options, whether it has been exercised
- Any transfer restrictions, lock-up provisions, or company approval requirements
- Estimated net proceeds after applicable taxes and transaction fees
- Whether partial liquidity — selling a portion rather than the full position — may be a better fit
Tools for Ro Health shareholders
Exploring equity in Ro Health often raises questions about taxes, exercise timing, valuation, and exit outcomes. These tools can help you model different decisions using your own assumptions.
Latest funding round
Ro Health most recently raised a Series D round in March 2022. The company was valued at $7B. Total funding raised to date is approximately $876M.
Lead investors in this round include General Catalyst and FirstMark Capital.
Founders & company background
Ro Health was founded in 2017 by Zachariah Reitano, Rob Schutz, Saman Rahmanian and is headquartered in New York, NY.
Investors
Industry
Similar private companies
Frequently asked questions
- Is Ro Health still a private company?
- Yes, Ro Health is currently a private company.
- What is Ro Health's latest funding round?
- Ro Health's most recent known round is Series D, raised in March 2022.
- What is Ro Health's valuation?
- Ro Health's latest reported valuation is $7B.
- Who are the investors in Ro Health?
- Notable investors include General Catalyst, FirstMark Capital, TQ Ventures, SignalFire.
- Can I sell my Ro Health stock?
- Private company shares can sometimes be sold on secondary markets. Speaking with a specialist who understands Ro Health stock can help you evaluate your options.
Related pages
Last verified: 2026-04-13 · Ro Health data compiled from funding disclosures, investor announcements, corporate filings, and public records.
Information on this page is compiled from publicly available sources and may be outdated or incomplete. This is not investment advice. Consult a qualified advisor before making financial decisions.